Login to Your Account



Already a life saver: AB2 Bio advancing its IL-18-binding protein

By Cormac Sheridan
Staff Writer

Tuesday, November 17, 2015

DUBLIN – Swiss orphan drug developer AB2 Bio Ltd. has obtained dramatic clinical proof of concept for its recombinant interleukin-18-binding protein (IL-18BP) therapy (tadekinig alfa), in an exceptional case involving an infant girl at risk of death from severe systemic inflammation.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription